Echocardiography results of protocol 3
| Protocol 3, day 6 . | Control . | Cfz . |
|---|---|---|
| . | n = 7 . | n = 8 . |
| HR | 636.28 ± 14.66 | 585.92 ± 10.58* |
| LVEDD, mm | 3.03 ± 0.07 | 3.08 ± 0.09 |
| LVESD, mm | 1.73 ± 0.04 | 1.86 ± 0.06 |
| LVPWd, mm | 0.76 ± 0.01 | 0.69 ± 0.01** |
| LVPWs, mm | 1.24 ± 0.02 | 1.17 ± 0.01** |
| FS, % | 43.03 ± 0.50 | 39.87 ± 0.47*** |
| r/h | 2.01 ± 0.05 | 2.21 ± 0.09 |
| Protocol 3, day 6 . | Control . | Cfz . |
|---|---|---|
| . | n = 7 . | n = 8 . |
| HR | 636.28 ± 14.66 | 585.92 ± 10.58* |
| LVEDD, mm | 3.03 ± 0.07 | 3.08 ± 0.09 |
| LVESD, mm | 1.73 ± 0.04 | 1.86 ± 0.06 |
| LVPWd, mm | 0.76 ± 0.01 | 0.69 ± 0.01** |
| LVPWs, mm | 1.24 ± 0.02 | 1.17 ± 0.01** |
| FS, % | 43.03 ± 0.50 | 39.87 ± 0.47*** |
| r/h | 2.01 ± 0.05 | 2.21 ± 0.09 |
Echocardiographic assessment of cardiac function in mice demonstrates significant reduction in FS% in Cfz vs control group (P < .001) at day 6 (*P < .05, **P < .01, ***P < .001).